Liver Transplantation and Metastatic Colo-rectal Cancer.
Phase 2
Active, not recruiting
- Conditions
- Colo-rectal Cancer
- Registration Number
- NCT00294827
- Lead Sponsor
- Oslo University Hospital
- Brief Summary
Survival of colo-rectal cancer patients after liver transplantation.
- Detailed Description
Survival, time to progression, other malignancy, side-effects, quality of life.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Colo-rectal cancer -
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Survival 6 years
- Secondary Outcome Measures
Name Time Method Time to progression side-effects 6 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie improved survival in metastatic colo-rectal cancer patients post-liver transplantation?
How does liver transplantation compare to systemic therapies like anti-EGFR or anti-VEGF agents in metastatic colo-rectal cancer outcomes?
Which biomarkers correlate with response to liver transplantation in KRAS-mutated or microsatellite unstable colorectal cancer subtypes?
What are the long-term adverse event profiles of liver transplant recipients with metastatic colorectal cancer?
Are there combination strategies involving liver transplantation and targeted therapies like BRAF inhibitors for metastatic colorectal cancer?
Trial Locations
- Locations (1)
Rikshospitalet-Radiumhospitalet HF
🇳🇴Oslo, Norway
Rikshospitalet-Radiumhospitalet HF🇳🇴Oslo, Norway